The estimated Net Worth of Daniel Karp is at least $244 Thousand dollars as of 12 February 2020. Mr. Karp owns over 960 units of Biogen Inc stock worth over $243,686 and over the last 6 years he sold BIIB stock worth over $0. In addition, he makes $0 as Executive Vice President and Corporate Development at Biogen Inc.
Daniel has made over 2 trades of the Biogen Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 960 units of BIIB stock worth $191,126 on 12 February 2020.
The largest trade he's ever made was exercising 960 units of Biogen Inc stock on 12 February 2020 worth over $191,126. On average, Daniel trades about 289 units every 56 days since 2018. As of 12 February 2020 he still owns at least 1,224 units of Biogen Inc stock.
You can see the complete history of Mr. Karp stock trades at the bottom of the page.
Daniel Karp has served as an Executive Vice President, Corporate Development of Biogen Inc. since June 2018. Prior to joining Biogen, Mr. Karp held a number of positions of increasing responsibility at Pfizer, a biopharmaceutical company, including as Vice President, Worldwide Business Development and Head of Business Development for Worldwide Research and Development from May 2016 to June 2018, as Vice President, Worldwide Business Development and BD Lead for Pfizer Vaccines, Oncology and Consumer Healthcare from January 2014 to May 2016, as Senior Director, Worldwide Business Development from December 2010 to December 2013, as Director, Worldwide Business Development from January 2008 to December 2010, as Senior Manager, Worldwide Business Development from May 2007 to December 2007 and as Manager, U.S. Business Development from July 2006 to April 2007. Prior to that, Mr. Karp held roles in healthcare and life sciences strategy consulting.
Daniel Karp is 41, he's been the Executive Vice President and Corporate Development of Biogen Inc since 2018. There are 24 older and no younger executives at Biogen Inc. The oldest executive at Biogen Inc is Stelios Papadopoulos, 72, who is the Independent Chairman of the Board.
Daniel's mailing address filed with the SEC is BIOGEN INC., 225 BINNEY ST., CAMBRIDGE, MA, 02142.
Over the last 21 years, insiders at Biogen Inc have traded over $166,883,156 worth of Biogen Inc stock and bought 665,319 units worth $183,001,783 . The most active insiders traders include Adam Koppel, Alexander J Denner, and Stelios Papadopoulos. On average, Biogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $2,343,090. The most recent stock trade was executed by Priya Singhal on 30 August 2024, trading 1,668 units of BIIB stock currently worth $332,082.
through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili
Biogen Inc executives and other stock owners filed with the SEC include: